Clinical trial
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With Human Immunodeficiency Virus Infected
NCT05105295 is registered in ClinicalTrials.gov with China National Biotec Group Company Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With Human Immunodeficiency Virus Infected
- Lead sponsor
- China National Biotec Group Company Limited
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- December 31, 2021
- Completion date
- June 30, 2022
- Enrollment
- 400 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.